MET and lymphoma: c-MET overexpression in cancer cells promotes survival of glioma and lymphoma cells via the PI3K signaling pathway and the proliferation of neck squamous cell carcinoma, gastric cancer, and prostate cancer cells via the MAPK and ERK signaling pathway (Figure 2) [42,43,44,45].